Meeting
2017 ASCO Annual Meeting
The “RENAISSANCE” Trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction—A phase III trial of the German AIO/CAO-V/CAOGI.
Authors
Daniel Wilhelm Mueller
Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany
Daniel Wilhelm Mueller , Stefan Paul Moenig , Arndt Vogel , Sylvie Lorenzen , Nils Homann , Christoph Reissfelder , Claus Bolling , Wolfgang Blau , Wolff H. Schmiegel , Patrick Michl , Karel Caca , Matthias Schwarzbach , Ralf Hofheinz , Claus Roedel , Manish A. Shah , Mitsuru Sasako , Wolf O. Bechstein , Hauke Lang , Claudia Pauligk , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02578368
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4140)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4140
Abstract #
TPS4140
Poster Bd #
127b
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
First Author: Ralf Hofheinz
Poster
2019 ASCO Annual Meeting
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
First Author: Salah-Eddin Al-Batran
Poster
2017 ASCO Annual Meeting
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.
First Author: Ralf Hofheinz
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama